Tandem Diabetes Care, Inc. (TNDM)
NASDAQ: TNDM · Real-Time Price · USD
15.34
+0.82 (5.65%)
At close: Oct 8, 2025, 4:00 PM EDT
15.34
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:10 PM EDT
Tandem Diabetes Care Revenue
Tandem Diabetes Care had revenue of $240.68M in the quarter ending June 30, 2025, with 8.46% growth. This brings the company's revenue in the last twelve months to $1.00B, up 25.84% year-over-year. In the year 2024, Tandem Diabetes Care had annual revenue of $940.20M with 25.74% growth.
Revenue (ttm)
$1.00B
Revenue Growth
+25.84%
P/S Ratio
0.96
Revenue / Employee
$378,007
Employees
2,650
Market Cap
1.04B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 940.20M | 192.49M | 25.74% |
Dec 31, 2023 | 747.72M | -53.50M | -6.68% |
Dec 31, 2022 | 801.22M | 98.42M | 14.00% |
Dec 31, 2021 | 702.80M | 203.97M | 40.89% |
Dec 31, 2020 | 498.83M | 136.53M | 37.68% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TNDM News
- 6 days ago - Tandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 9 days ago - Tandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United States - Business Wire
- 17 days ago - TNDM Investors Have Opportunity to Join Tandem Diabetes Care, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 22 days ago - Tandem Diabetes Care Announces Publication Showing Adults With Type 2 Diabetes Benefit from Automated Insulin Delivery Regardless of C-Peptide Levels - Business Wire
- 4 weeks ago - Tandem Diabetes Care, Inc. (TNDM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 weeks ago - Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones - Business Wire
- 2 months ago - Top 3 Health Care Stocks That Are Preparing To Pump This Month - Benzinga
- 2 months ago - Tandem Diabetes Care: An Earnings Miss Confirms The Bear Case - Downgrade To Sell - Seeking Alpha